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introduction: Glutathione S-transferase alpha (GSTA) and matrix metalloproteinase-7 (MMP-7), ubiquitously expressed in the body, are enzymes 
with antioxidant properties that either detoxify reactive metabolites originating from lipid peroxidation or regulate expression of anti-oxidant protein 
peroxiredoxin, respectively. AF is known to be associated with myocardial oxidative stress and anti-oxidants have shown to have anti-arrhythmic 
benefits. This prospective study examined the correlation between baseline GSTA and MMP-7 and procedure outcome after catheter ablation in AF.
methods: Forty-eight consecutive patients (age 63±5 year, 71% male, paroxysmal 39%, persistent 46%, long-standing persistent AF 15%, BMI 
31±6) undergoing catheter ablation were prospectively enrolled in this pilot study. Patients with chronic inflammatory conditions or taking anti-
inflammatory drugs were excluded. Fasting blood samples were collected within 24-hours pre-ablation. Patients were followed up for 12±3 months 
for AF recurrence by cardiology evaluation, EKG and 7-day Holter monitoring.
results: Baseline blood samples were analyzed for GSTA and MMP-7 by an enzyme-linked immunosorbent (ELISA) assay. Patients were stratified 
into two age groups, <65 years (n=32) and ≥65 years (n=16). The biomarker levels were significantly higher in ≥65 year patients compared to 
<65 (GSTA: 25.9±13.4 vs. 10.9±7.6, p .01; MMP-7: 6.9±2.2 vs. 4.7±1.9, p<.001). Outcomes were evaluated by Cox proportional hazards models 
adjusting for gender and AF type. In ≥65 year cohort the level of GSTA [hazard ratio (HR) 0.80 (0.66-0.97), p=.024] and MMP-7 [HR 0.23 (0.07-
0.81), p=.023] strongly predicted arrhythmia recurrence. However, no such relation was observed in <65 group [GSTA: HR 0.98 (0.91-1.1), p=.74; 
MMP-7: HR 1.22 (0.89-1.7), p=.23].
conclusion: Elevated baseline levels of GSTA and MMP-7 are associated with lower recurrence rate only in AF patients aged ≥65 years, but not in 
those aged <65. As age-related oxidative stress is higher in elderly, it is possible that they incurred more benefit from elevated level of anti-oxidant 
cytokines than the younger population.
